Back to Search

DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer

  • Protocol Number: 202407134
  • Principal Investigator: Grierson, Patrick
  • Cancer Types: Gastrointestinal

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.

Protocol Interventions

Drug: Gemcitabine, Drug: Cisplatin, Drug: Durvalumab, Diagnostic Test: Agilent HercepTest™ mAb pharmDx, Diagnostic Test: Ventana PD-L1 SP263 assay